ODDB.org: Open Drug Database | Medikamente

Suchresultat - FI zu Tibolon-Mepha

Fachinformation zu Tibolon-Mepha:

Mepha Pharma AG

G03CX01 - Tibolone

ATC-DDD Version 2016. Source: WHO

G - Genito Urinary System and Sex Hormones

G03 - Sex Hormones and Modulators Of The Genital System

Other hormones, see H - Systemic hormonal preparations, excl. sex hormones and insulins.
Sex hormones used only in the treatment of neoplastic diseases (often selected strengths) are classified in L - Antineoplastic and immunomodulating agents.

The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability. The DDDs of depot preparations are calculated as the dose divided by the dosing interval.

G03C - Estrogens

This group comprises estrogens and combinations, except combinations with
- androgens, see G03E
- progestogens, see G03F
- antiandrogens, see G03HB
Hormonal contraceptives, see G03A.
Estrogens used only in neoplastic diseases, see L - Antineoplastic and immunomodulating agents.

The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments. However, for some preparations for vaginal administration the DDDs are based on local treatment.
The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.

G03CX - Other Estrogens

Tibolone is classified in this group even though the chemical structure is different from the other estrogens.

G03CX01 - Tibolone

Stärke	Adm.Route	Note
	O

2025	©ywesee GmbH